ArticleFrontiers in oncology2025
Expression of SMURF family in pancreatic cancer and its effect on cell proliferation and migration.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the expression of Smad ubiquitination regulatory factors (SMURFs) in pancreatic cancer and analyze their relationship with cancer staging and prognosis, and to investigate the potential of SMURF as a therapeutic target for pancreatic cancer. Methods: A total of 179 patients with pancreatic cancer were identified in The Cancer Genome Atlas (TCGA) database. This dataset was utilized in the study to analyze the expression of SMURF1 and SMURF2 and their correlation with pancreatic cancer staging and patient survival. Results: High expression of SMURF1 showed a significant positive correlation with T staging, histological and pathological grades, as well as clinical treatment outcomes of pancreatic cancer ( Conclusion: High expression of SMURF1 could potentially be a therapeutic target and a poor prognostic indicator in pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.